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a IndiaBackground: Metabolic syndrome is associated with the development of diabetes mellitus and cardiovascular
disease. The impact of metabolic syndrome on the progression of atherosclerosis has been well documented. This study
was designed to evaluate the impact of metabolic syndrome on global left ventricular function by using left ventricular
myocardial performance index (LVMPI).
Methods: The diagnosis of metabolic syndrome was made as per the criteria of the International Diabetes
Federation. Echocardiography was performed with a Philips IE33 machine using a 1–5 MHz transthoracic probe.
LVMPI was calculated by adding isovolumic contraction time with isovolumic relaxation time and dividing it by
ejection time.
Results: The mean LVMPI value in metabolic syndrome was 0.64 ± 0.09, while that in controls was 0.48 ± 0.06
(p < 0.001). Metabolic syndrome was seen to have more significant influence on LVMPI.
Conclusions: Metabolic syndrome is a strong predictor of sub-clinical myocardial dysfunction in subjects free of
clinically apparent heart disease.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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timeIntroduction
Metabolic syndrome (MetS) constitutes a con-stellation of metabolic abnormalities that
confer an increased risk of cardiovascular disease
and diabetes mellitus (DM). Although the impact
of MetS on the progression of atherosclerosis hasbeen well documented, its effects on left ventricular
function have not been extensively evaluated
[1–3]. Metabolic syndrome is considered to be an
independent risk factor for heart failure.
At least one third of patients with heart failure
have both systolic and diastolic dysfunction. A
Abbreviations
MetS metabolic syndrome
LVMPI left ventricular myocardial performance index
IDF International Diabetes Federation
IVCT isovolumic contraction time
IVRT isovolumic relaxation time
ET ejection time
TDI tissue Doppler imaging
PWD pulse wave Doppler
BMI body mass index
IFG impaired fasting glucose
SBP systolic blood pressure
DBP diastolic blood pressure
DM diabetes mellitus
FBS fasting blood sugar
TGL triglycerides
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(Tei index), combining both systolic and diastolic
time intervals was introduced in 1995 [4,5]. This
index, represented by the sum of isovolumic relax-
ation time (IVRT) and isovolumic contraction time
(IVCT) divided by left ventricular ejection time
(ET), is reported to be a sensitive measure of global
left ventricular performance. Myocardial perfor-
mance index can be determined easily using con-
ventional Doppler echocardiography.
Hence, this study was designed to evaluate the
impact of MetS on global left ventricular function
by using left ventricular myocardial performance
index (LVMPI) and to compare it with healthy
controls.HDL-C high density lipoprotein cholesterol
MPI myocardial performance indexMaterials and methods
We recruited 50 consecutive patients with MetS
attending to the Cardiology Out-patient Depart-
ment of Sri Venkateswara Institute of Medical Sci-
ences into this prospective case-control study. The
diagnosis of MetS was made as per the Interna-
tional Diabetes Federation (IDF) criteria [6].
According to this criteria, diagnosis of MetS was
performed with waist circumference P90 cm for
men or P80 cm for women (for South-Asian eth-
nic group) along with any two of the following: tri-
glyceride (TGL) levels P150 mg/dL or treatment
for elevated TGL, HDL Cholesterol (HDLC) levels
P40 mg/dL for men or P50 mg/dL for women;
blood pressure P130/85 mmHg or undergoing
antihypertensive treatment, and fasting blood glu-
cose levels P100 mg/dL or treatment for DM.
The study excluded patients aged above
60 years, patients with structural heart disease,
including valvular and ischemic heart disease,
patients with atrial fibrillation, atrial flutter and
AV blocks, patients with other secondary causes
of hyperlipidemia like hypothyroidism and renal
insufficiency. Thirty age- and sex-matched healthy
controls were recruited into the control cohort.
Informed consent was obtained from each of the
patients and controls following ethical guidelines
of the 1975 Declaration of Helsinki. This study
was approved by the Institutional Ethical Commit-
tee of Sri Venkateswara Institute of Medical Sci-
ences, Tirupati, Andhra Pradesh, India.
Baseline assessment in all patients included a
detailed history, physical examination, and cardiovas-
cular examination. Risk factors like diabetes mellitus,
hypertension and obesity were assessed. Anthropo-
metric evaluation included waist circumference which
was measured to the nearest centimeter, just above
the iliac bones, with the subject standing using a flex-
ible and non-distensible tape. Waist circumference>90 cm was considered as abdominal obesity. Blood
pressure was measured twice with a three-minute
interval after a 10-min rest with no tight clothes. The
mean of the two measurements was recorded. Obesity
was defined as body mass index (BMI) greater
than 30 kg/m2. Plasma glucose, serum triglycerides
and serum HDL cholesterol levels were measured
using commercially available kits on auto analyzer
(Synchron CX9 from Beckman, USA).
Echocardiography was performed with a Philips
IE33 (Philips, The Netherlands) machine using a
1–5 MHz transthoracic probe, according to the
guidelines of the American Society of Echocardi-
ography [7]. A parasternal long axis view approx-
imately at the level of the mitral valve leaflet tips
was used to measure LV wall thickness, end sys-
tolic and end diastolic dimensions. The mitral
inflow velocity pattern was recorded in the apical
4-chamber view with the pulsed wave Doppler
sample volume positioned at the tip of mitral leaf-
lets during diastole. The left ventricular outflow
velocity pattern was recorded in the apical 5-
chamber view with the pulse wave Doppler vol-
ume positioned just below the aortic valve [8].
Both ventricular inflow and outflow patterns
were recorded at 100 mm/s sweep speed. Doppler
measurements were obtained by an average of
five consecutive beats as described by Quiñones
et al. [8]. Doppler time intervals were measured
from the mitral inflow and left ventricular outflow
velocity time intervals. The interval between
mitral valve closure and opening corresponds to
the time from cessation to onset of mitral inflow
and is equal to the sum of IVCT, ET, and the IVRT.
Left ventricular ejection time was measured as the
duration of the left ventricular outflow velocity
profile. Then, myocardial performance index
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IVRT, dividing it by ET. In Doppler tissue imaging,
the sample volume was positioned at the medial
end of the mitral annulus. Isovolumic contraction
time (IVCT) was calculated from mitral valve clo-
sure to the aortic valve opening (end of Am to
onset of Sm). Ejection time (ET) was calculated
from onset of Sm to end of Sm. Isovolumic relax-
ation time (IVRT) was calculated from aortic valve
closure to mitral valve opening (end of Sm to
onset of Em). LVMPI was calculated by adding
IVCT + IVRT, and dividing it by ET. The LVMPI
was then compared with the controls of the non-
MetS group [9,10].Statistical analysis
Data was expressed as mean ± SD for continuous
variables and numbers with percentages for categor-
ical variables. For quantitative variables, Student’s t-
test was used to compare the difference in mean val-
ues in the two groups. The association between cate-
gorical variables and the outcome was evaluated by
v2 test or Fisher’s exact test as appropriate. Results
with p < 0.05 were considered to be significant. Step-
wise linear regression analysis was used for studying
the relationship of LVMPI with the study variables.
The correlation between LVMPI derived from tissue
Doppler imaging (TDI) and the conventional pulse
wave Doppler (PWD) imaging was studied. Statisti-
cal analysis was performed with SPSS 20.0 (IBM Cor-
poration, Chicago, IL, USA).Results
Mean age of cases was 40.84 years and that of
controls was 44.03 years, with no significant differ-Table 1. Comparison of Demographic and Clinical characteristics.
Characteristic MetS group
Sex (M/F) 28/22
Age (years) 40.84 ± 6.58
Height (cm) 159.09 ± 21.46
Weight (kg) 76.25 ± 13.62
BMI (kg/m2) 29.05 ± 4.81
Waist circumference (inch) 99.42 ± 13.63
Triglycerides (mg/dL) 259.04 ± 208.97
HDLC (mg/dL) 36.92 ± 4.98
SBP (mmHg) 132.00 ± 13.48
DBP (mmHg) 88.50 ± 9.98
FBS (mgs%) 112.84 ± 16.71
LVMPI-TDI 0.64 ± 0.09
LVMPI-PWD 0.63 ± 0.08
MetS: metabolic syndrome; M: male; F: female; BMI: Body mass index; HDLC
diastolic blood pressure; FBS: fasting blood sugar; LVMPI: left ventricular m
wave Doppler.
* Indicates a significant p-value (p < 0.05).ence (p = 0.089). Thirty-eight percent of cases (19/
50) were obese in comparison to 13.3% (4/30) of
controls. Mean BMI value in cases was
29.05 ± 4.81, while in controls it was 24.75 ± 4.02
(p = 0.0001). BMI was higher in cases than in con-
trols as obesity is an exogenous risk factor for
MetS. All the cases had abdominal obesity as per
the inclusion criteria while 60% of the controls
(18/30) had abdominal obesity (p < 0.0001).
Incidence of hypertension in cases was 52% (26/
50), while in controls it was 3.3% (1/30) (p < 0.0001).
In cases, 48% (24/50) were normotensives. In cases,
68% (34/50) were hyperglycemic in contrast to 10%
(3/30) in controls (p < 0.0001). Among the cases,
10% (5/50) had impaired fasting glucose (IFG). Com-
parison of all demographic and clinical characteris-
tics of the study population are summarized and
compared with and without MetS groups in Table 1.
Seventy-four percent of cases (37/50) had
hypertriglyceridemia, whereas only 10% of
controls (3/30) had higher triglyceride values.
The mean value of triglycerides in cases was
259.04 ± 208.97 mg/dl, and in controls it was
130.50 ± 89.71 mg/dl (p = 0.002).
Eighty-two percent of cases (41/50) had low
HDL-C levels, whereas 46.7% of controls (14/30)
had low HDL-C levels. The mean value of HDL-
C in cases was 36.92 ± 4.98 mg/dl, and was
40.70 ± 7.70 mg/dl (p = 0.009) in controls. The influ-
ence of each studied variable on LVMPI in the
study population is summarized in Table 2.Distribution of LVMPI by tissue Doppler imaging
in the study population
The mean LVMPI value in cases was 0.64 ± 0.09,
while in controls it was 0.48 ± 0.06 (p < 0.0001). InControl group p-Value
18/12 0.90
44.03 ± 9.95 0.09
164.40 ± 9.04 0.20
67.07 ± 12.77 0.004*
24.75 ± 4.02 0.0001*
87.10 ± 10.47 <0.0001*
130.50 ± 89.71 0.002*
40.70 ± 7.71 0.009*
112.00 ± 9.81 <0.0001*
73.36 ± 6.86 <0.0001*
84.03 ± 13.37 <0.0001*
0.48 ± 0.06 <0.0001*
0.48 ± 0.05 <0.0001*
: high density lipoprotein cholesterol; SBP: systolic blood pressure; DBP:
yocardial performance index; TDI: tissue Doppler imaging; PWD: pulse
Table 3. Stepwise Multiple Linear regression analysis.
Variable Unstandardized coefficient Standardized coefficient Beta t p-Val
B Std. Error
Waist circumference 0.0029 .001 .376 2.120 .040*
BMI 0.000 .003 .009 0.052 .959
SBP 0.007 .021 .065 0.410 .691
DBP 0.009 .030 .072 0.614 .322
Triglycerides 0.0002 .000 .322 3.417 .001*
HDL-C 0.003 .003 .169 1.168 .249
FBS 0.104 .043 .317 2.342 .024*
LVMPI as dependent variable and other variables as independent variables.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL-C: High density lipoprotein cholesterol; FBS: fasting blood
sugar.
* Indicates a significant p-value (p < 0.05).
FU
LL LEN
G
TH
 A
RTIC
LE
Table 2. Influence of each variable on the LVMPI in the study population.
Variable (n) LVMPI p-Val for effect of each variable on the study population
Obese (n = 23) 0.617 ± 0.11
Non-obese (n = 57) 0.572 ± 0.11 0.101
Visceral obesity (n = 68) 0.606 ± 0.103
Non-visceral obesity (n = 12) 0.466 ± 0.064 <0.0001*
Hypertension (n = 27) 0.634 ± 0.074
Normotensives (n = 53) 0.561 ± 0.12 0.005*
IFG/Diabetes (n = 37) 0.629 ± 0.096
Normoglycemics (n = 43) 0.548 ± 0.11 0.0008*
Hypertriglyceridemia (n = 40) 0.635 ± 0.088
Normal triglycerides (n = 40) 0.535 ± 0.108 <0.0001*
Decreased HDL-C (n = 55) 0.598 ± 0.102
Normal HDL-C (n = 25) 0.558 ± 0.125 0.134
LVMPI: left ventricular myocardial performance index; IFG: impaired fasting glucose; HDL-C: high density lipoprotein cholesterol.
* Indicates a significant p-value (p < 0.05).
148 SREENIVASA KUMAR ET AL
IMPACT OF METABOLIC SYNDROME ON GLOBAL LEFT VENTRICULAR FUNCTION:
AS EVALUATED BY THE MYOCARDIAL PERFORMANCE INDEX
J Saudi Heart Assoc
2014;26:145–151our study, the components of MetS were seen to
have significant influence on LVMPI. The impor-
tant influencing parameters on LVMPI were iden-
tified with the help of Stepwise Multiple Linear
Regression analysis. With the Stepwise Multiple
Linear Regression analysis model, high waist cir-
cumference, high triglycerides and fasting blood
sugars were found to be the most influencing vari-
ables and were associated with an increased
LVMPI (Table 3).
LVMPI by conventional pulse wave Doppler
method
Mean LVMPI with conventional pulse wave
Doppler imaging in cases was 0.63 ± 0.08, while
in controls, it was 0.48 ± 0.05. Mean LVMPI by con-Table 4. Comparison of LVMPI by Pulse wave Doppler and tissue
Mean N Std. De
LVMPI (PWD) 0.575 80 0.1029
LVMPI (TDI) 0.583 80 0.1124
LVMPI: left ventricular myocardial performance index; PWD: pulse wave Dventional pulse wave Doppler method was signif-
icantly high in cases when compared to controls
(p < 0.0001).
Comparison of means of LVMPI obtained by
conventional pulse wave Doppler and tissue
Doppler imaging is shown in Table 4. There was
no significant difference in the mean LVMPI
between the two methods (p = 0.08). The correla-
tion between the two methods for measuring
LVMPI was also good (r = 0.941).Discussion
The main finding of the present study is that
MetS is associated with abnormal myocardial per-Doppler imaging:
viation Std. error Mean Sig.
.0115 t-value = 1.728
r = 0.941
p-val = 0.08
.0126
oppler; TDI: tissue Doppler imaging.
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Asian-Indian population.
The mean value of BMI was 29.05 ± 4.81 in our
study cases, while in the study by Turhan et al.
[11] it was 30 ± 4, both of which are comparable.
Twenty-nine percent of the study population had
obesity (BMI > 30 kg/m2) with higher mean
LVMPI values than in non-obese cases
(0.62 ± 0.11 vs 0.57 ± 0.11, p = 0.121). This is in
accordance with a study published by Dayi et al.
where weight loss was associated with a decrease
in LVMPI values [12]. Using a cutoff value of
BMIP 30 kg/m2, 38% of cases and 13.3% of con-
trols were obese. In their recent guidelines, the
Indian Council of Medical Research (ICMR) low-
ered the BMI threshold for Indians due to the
higher incidence of insulin resistance than their
western counterparts [13]. According to this
classification, BMI of less than 18.4 kg/m2 is
underweight, 18.5–22.9 kg/m2 is normal, 23–24.9
kg/m2 is overweight, and more than or equal to
25 kg/m2 is considered obese. Using this new clas-
sification, 76% of cases and 44% of controls were
obese.
We also found that visceral obesity assessed by
waist circumference is more predictive of MetS
than obesity assessed by BMI. This was explained
by the fact that among our cases all had abdomi-
nal obesity by definition and only 38% were obese
(BMI > 30 kg/m2). This is in accordance with the
finding that increased intra-abdominal fat is asso-
ciated with worse metabolic profile and elevated
pro-inflammatory cytokines, as in the study pub-
lished by Després and Limieux in Nature in 2006
[14]. The same finding was also noted in the study
by Voulgari et al. [15].
In the present study, 66% of the study popula-
tion were normotensives with higher LVMPI val-
ues (0.561 ± 0.12). This shows that MetS per se,
irrespective of hypertension, is associated with
changes in cardiac function. This is in accordance
with the study by Voulgari et al., which found that
18% of cases were normotensives with higher
LVMPI values [15]. The Strong Heart Study
reported worse left ventricular function in sub-
jects with MetS, and a history of hypertension
was the strongest predictor of changes in left ven-
tricular geometry followed by other components
of MetS [16].
In our present study, MetS as a whole was seen
to have a more significant influence on LVMPI
than each of its individual components. In
Women’s Health Study, cardiovascular mortality
was found to increase linearly as the number of
components of MetS increased [3].In the evaluation of left ventricular function it is
important to use the parameters that reflect both
systolic and diastolic dysfunction, as approxi-
mately one-third of heart failure patients have
impairment of both systolic and diastolic dysfunc-
tion. In the assessment of the Tei index, left ven-
tricular systolic dysfunction shortens ejection
time and prolongs IVCT, while left ventricular dia-
stolic dysfunction prolongs IVRT. The Tei index
has proved to be more effective for analysis of glo-
bal myocardial performance than systolic or dia-
stolic indices alone [17]. Additionally, data have
shown that a higher value of the Tei index is asso-
ciated with increased cardiovascular risk [18].
Although the impact of obesity and diabetes on
left ventricular function has been studied exten-
sively, there are a few studies that demonstrate
the effects of MetS on left ventricular function.
Further, it was found that patients with idiopathic
dilated cardiomyopathy have high prevalence of
insulin resistance, suggesting a possible link with
MetS [19]. In this regard, we evaluated left ventric-
ular function in MetS with the Tei index.
Previous studies have shown abnormal myocar-
dial performances in MetS. A study by Chinali
et al. has shown significant alteration in diastolic
function using echocardiographic examination in
American Indians with MetS [20]. Wong et al.
showed impairment of both systolic and diastolic
dysfunction in MetS using global strain rate [21].
Dutta et al. evaluated the impact of insulin resis-
tance on cardiomyocyte function in sucrose fed
rats and showed that contraction and relaxation
are prolonged with insulin resistance. They
hypothesized that alteration in matrix proteins
caused by the accumulation of advanced glycation
end products can lead to increased stiffening of
the heart [22]. Rutter et al. in the Framingham
Heart sub study on the impact of insulin resis-
tance on cardiac function found significant short-
ening of ET in patients of insulin resistance. This
shortening of ET is mainly related to left ventricu-
lar systolic dysfunction and can lead to an increase
in LVMPI values. In the Framingham off spring
study, progressively increasing glucose intoler-
ance is associated with increasing left ventricular
mass and wall thickness [23].
The present study has a higher mean Tei index
value in its study population (0.64 ± 0.09 vs
0.48 ± 0.06, p- < 0.001) than previous studies done
by Turhan et al. (0.55 ± 0.06 vs 0.38 ± 0.04, p <
0.001); and Voulgari et al. (0.41 ± 0.04, p < 0.001)
[11,15]. This can be explained by the fact that the
incidence of metabolic risk factors like hyperten-
sion, diabetes and dyslipidemia were higher in a
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factors.
In the multivariate analysis of the present study,
variables of MetS which were shown to have a
strong association with the Tei index are waist cir-
cumference, and high TGL and FBS levels. In the
study by Voulgari et al. [15] variables shown to
have a strong association with the Tei index were
high blood glucose, hypertension, and low HDL-C
levels. The regression analysis of our study
implies that patients can have abnormal myocar-
dial performance values based on the perfor-
mance of these three variables.
Our study also found that the Tei index is more
sensitive than conventional systolic or diastolic
indices. Left ventricular systolic function as
assessed by LVEF was normal in the entire study
population, and diastolic function as assessed by
E/A ratio and Em was also normal in a significant
number of study participants. In a prospective
study by Tei et al. LVMPI better correlated with
the TAU index (left ventricular relaxation time
constant) assessed invasively, than conventional
diastolic indices [24].
With the above findings, it is apparent that diag-
nosis of abnormal myocardial performance in
patients of MetS can be made with the help of
LVMPI when most of the conventional systolic
and diastolic indices are normal. Left ventricular
myocardial performance index (LVMPI) is useful
not only for evaluating ventricular function but
also the impact of the therapeutic approach on
myocardial function.
Mean LVMPI as estimated by conventional
pulse wave Doppler imaging was significantly
increased in cases than in controls (0.63 vs 0.48,
p < 0.001). LVMPI, as estimated by conventional
pulse wave Doppler, correlated well with that esti-
mated by tissue Doppler imaging (r = 0.941). A
study by Tekten et al. [10] shows that LVMPI by
both methods had good correlation.
Evidently, MetS adds important prognostic infor-
mation in terms of cardiovascular risk prediction.
Additionally, recent data demonstrate that MetS is
associated with a twofold increased risk of heart fail-
ure irrespective of established risk factors including
myocardial infarction [25]. The recent guidelines for
the management of hypertension suggest that blood
pressure levels of more than 130/85 mmHg in these
patients should be treated [26].Conclusions
Metabolic syndrome is a strong predictor of myo-
cardial dysfunction in subjects free of clinicallyapparent heart disease. Strategies should aim at
prevention of MetS to reduce the cardiovascular
burden and risk of heart failure.Limitations
1. Load dependency of the Tei index: This is
important in critically ill patients who have
acute changes in pre load and after load. But
the majority of our patients were hemodynam-
ically stable. Further, measurement of the Tei
index by tissue Doppler is independent of load
changes.
2. Pseudo normalization of the Tei index: As dia-
stolic pressures increase to restrictive filling
states the Tei index decreases due to decrease
in IVRT. However, the majority of our patients
were in Grade I diastolic dysfunction.
3. The Tei index, determined by tissue Doppler
imaging, takes into consideration only myocar-
dial fiber shortening along its long axis. Cir-
cumferential fiber shortening is not taken into
consideration.
4. Open label study.
5. Possibility of sub clinical coronary artery dis-
ease in the study population.Acknowledgement
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